Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Medipal Holdings (7459 JP): Largest Investor’s Pressure Aims to Enhance Shareholder Value

Medipal Holdings (7459 JP): Mixed FY24 Result; Growth to Continue in FY25; Buyback Plan Announced

Medipal Holdings (7459 JP): Better-Than-Expected FY23 Result; Accelerated Growth Expected in FY24

Medipal Holdings (7459 JP): Started FY24 On a Strong Note with Accelerated Revenue

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medipal-holdings-corp" target="_blank" data-smartkarma-citation="entities:18394:1" rel="noopener">Medipal Holdings (7459 JP)</a> intends to acquire a minimum of 8.7M shares of <a href="https://www.smartkarma.com/entities/paltac-corporation" target="_blank" data-smartkarma-citation="entities:20014:1" rel="noopener">Paltac Corporation (8283 JP)</a> (representing ownership ratio of 14.3%) to make it a wholly owned subsidiary.</li>
<li>Medipal will conduct tender offer to acquire all of the Paltac shares at ¥6,650 per share, representing a premium of 43% to the undisturbed closing price.</li>
<li>Converting Paltac into a wholly owned subsidiary will make Medipal a unique wholesale and distribution company. The combination of high productivity and expertise should create best-in-class logistics.</li>
</ul>



Medipal Holdings (7459 JP) intends to acquire a minimum of 8.7M shares of Paltac Corporation (8283 JP) (representing ownership ratio of 14.3%) to make it a wholly owned subsidiary.
Medipal will conduct tender offer to acquire all of the Paltac shares at ¥6,650 per share, representing a premium of 43% to the undisturbed closing price.
Converting Paltac into a wholly owned subsidiary will make Medipal a unique wholesale and distribution company. The combination of high productivity and expertise should create best-in-class logistics.


Medipal Holdings (7459 JP): Paltac (8283 JP) Acquisition to Release Margin Pressure